GoToWebinar 007.png

We offer many CBD formulations, including oils, tinctures, creams, capsules and salves from Ananda Professional. Our CBD products are available over-the-counter and do not require a prescription.

CBD products are being used to promote better sleep, reduce anxiety, and help manage chronic pain.

Not all CBD products are created equal. Some CBD products are mislabeled or may contain THC in amounts greater than allowable.

When you buy our CBD products, you can be sure you are getting a product that is:

  • High quality
  • 100% legal with less than 0.3% THC
  • Non-psychoactive with no known side effects

Contact us today for more information on the CBD products we carry and see if CBD may be right for you. We are happy to discuss and provide you with all the information you need on CBD products.

    Cannabinoids and Pain

    Pain is one of the most frequent health complaints. In the United States, “back pain” is the most common chief complaint at medical offices and emergency rooms. Cannabinoids have an important role in pain relief. It works in at least two ways to improve pain: by modulating inflammatory responses that cause pain and by reducing nociceptive thresholds in both the central nervous system and the periphery. In other words, cannabinoids work by stopping pain at its source and by decreasing the perception of pain. CBD primarily alters activity in CB2 receptors. CB2 receptors contribute to “antinociception by inhibiting the release of pro-inflammatory factors by non-neuronal cells located near nociceptive neuron terminals,” specifically in inflammatory hyperalgesia and neuropathic pain, (Manzanares et al., 2006, p 240). Cannabinoids may indirectly influence NMDA receptor activity and control NMDA receptor over activation in neuropathic pain pathways (Sanchez-Blazquez et al., 2014). Additionally, CBD is a positive allosteric modulator at α1 and α 1 β glycine receptors (Xiong et al., 2012).

    The most research on cannabinoids has been in the areas of pain. Many studies have investigated pain as their primary outcome, but dozens of studies with other primary outcomes, such as HIV, cancer, spasticity, etc., have also evaluated pain as a secondary outcome. The results are overwhelmingly supportive that cannabinoids are affective analgesics.

    Three systematic reviews concluded that cannabinoids are affective analgesics. Whiting et al.’s systematic review in JAMA included 28 clinical trials evaluating cannabinoids and pain. The authors concluded that there is moderate-quality evidence that cannabinoids may result in marked pain reduction, (Whiting et al., 2015). A second systematic review on neuropathic pain included fifteen randomized controlled trials found that cannabinoids were more effective than placebos, but warned about possible minor adverse events, such as intoxication. Intoxication was due to higher levels of THC, which are not found in hemp products (Petzke et al., 2016). Lastly, the National Academies of Science, Engineering and Medicine conducted an extensive systematic review aimed at evaluating cannabinoid therapies and safety (2017). They reached nearly 100 conclusions. One of them is that there is “extensive evidence” of cannabinoids’ efficacy in pain relief. They also concluded that cannabinoids are well-tolerated. Finally, the study authors remarked that cannabinoid therapy or supplementation may play a role in reducing opioid intake.

    Manzanares, J., Julian, M. D., & Carrascosa, A. (2006). Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Current neuropharmacology, 4(3), 239-257.

    National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press.

    • Petzke, F., Enax-Krumova, E. K., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies.Schmerz (Berlin, Germany), 30(1), 62-88.

    • Sánchez-Blázquez, P., Rodríguez-Muñoz, M., & Garzón, J. (2014). The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Frontiers in pharmacology, 4, 169.

    • Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., ... & Schmidlkofer, S. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. Jama,313(24), 2456-2473.

    • Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S. R., Willenbring, D., ... & Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. Journal of Experimental Medicine, jem-20120242.